{
    "clinical_study": {
        "@rank": "151284", 
        "arm_group": [
            {
                "arm_group_label": "sumatriptan+promethazine (SPr)", 
                "arm_group_type": "Active Comparator", 
                "description": "The SPr group denote patients receiving oral sumatriptan (50 mg) plus oral promethazine (50 mg)."
            }, 
            {
                "arm_group_label": "Sumatriptan+placebo (SP)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The SP group denote patients receiving oral sumatriptan (50 mg) plus tablet of placebo matched to promethazine."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to show the efficacy of promethazine in management of patients\n      with moderate to severe migraine"
        }, 
        "brief_title": "Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Migraine With Aura", 
            "Migraine Without Aura"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Migraine Disorders", 
                "Migraine with Aura", 
                "Migraine without Aura"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who aged 18 to 65 years with a clinical history of migraine with or without\n             aura (International Headache Society categories 1.1 or 1.2) for at least 1 year\n\n          -  Subjects who have mean frequency of 2-8 migraine attacks per month.\n\n        Exclusion Criteria:\n\n          -  Complex form of migraine, medication overuse headache, history of chronic\n             tension-type headache, ophthalmoplegic, basilar and hemiplegic migraine\n\n          -  Uncontrolled hypertension (diastolic blood pressure >95 mm Hg or systolic blood\n             pressure >160 mm Hg)\n\n          -  History or clinical evidence of cerebrovascular or cardiovascular disorder\n\n          -  Renal impairment or dialysis dependence\n\n          -  Serious illness (physical or psychiatric disorders)\n\n          -  Drugs and alcohol abuse\n\n          -  Pregnancy and breastfeeding\n\n          -  Allergy or hypersensitivity to promethazine or triptans\n\n          -  Concurrent use of ergotamine-containing drugs, monoamine oxidize inhibitors,\n             antidepressant, lithium"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01814189", 
            "org_study_id": "SB-045"
        }, 
        "intervention": {
            "arm_group_label": [
                "sumatriptan+promethazine (SPr)", 
                "Sumatriptan+placebo (SP)"
            ], 
            "intervention_name": "Sumatriptan+Promethazine (SPr)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Promethazine", 
                "Diphenhydramine", 
                "Sumatriptan"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Tehran", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "17666-33812"
                }, 
                "name": "Department of Neurology, Emam Hossein Hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint variable was the proportions of patients reporting complete headache relief 2 hours after dosing.", 
            "measure": "Complete headache relief", 
            "safety_issue": "No", 
            "time_frame": "At 2 hours after first dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01814189"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Shaheed Beheshti Medical University", 
            "investigator_full_name": "Shadi Asadollahi", 
            "investigator_title": "Research Assistant of Neurology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The secondary endpoint variable was the proportions of patients reporting complete headache relief 0.5 hour, 1 hour, and 4 hours after dosing.", 
                "measure": "Complete headache relief", 
                "safety_issue": "No", 
                "time_frame": "At 0.5 hour, 1 hour, and 4 hours after first dose"
            }, 
            {
                "description": "The secondary endpoint variable was the proportion of patients experiencing headache improvement at 0.5 hour, 1 hour, 2 hours, 4 hours after dosing.", 
                "measure": "Headache improvement.", 
                "safety_issue": "No", 
                "time_frame": "At 0.5 hour, 1 hour, 2 hours, 4 hours after first dose."
            }, 
            {
                "description": "The secondary endpoint variable was the use of second dose when the severity of headache was still moderate or severe after the first dose within 2-48 hours", 
                "measure": "Using the second dose of study medications.", 
                "safety_issue": "No", 
                "time_frame": "At 2-48 hours after first dose."
            }, 
            {
                "description": "The secondary endpoint variable was the use of rescue medication (excluding triptans, and ergot-containing medication) within 4-48 hours after the second dose when headache severity was still at grade 2 \u2044 3.", 
                "measure": "Using rescue medication between 2 and 48 hours postdose", 
                "safety_issue": "No", 
                "time_frame": "At 4-48 hours after second dose."
            }, 
            {
                "description": "The secondary endpoint variable was a return to moderate or severe pain within 48 hours of first dose subsequent to primary improvement to mild or no pain at 2 hours.", 
                "measure": "Rate of headache recurrence", 
                "safety_issue": "No", 
                "time_frame": "At 2-48 hours after first dose."
            }, 
            {
                "description": "Presence or absence of adverse events occurred 4 hours after first dosing.", 
                "measure": "Occurrence of adverse events.", 
                "safety_issue": "Yes", 
                "time_frame": "At 4 hours after first dose."
            }
        ], 
        "source": "Shahid Beheshti Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shahid Beheshti Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}